A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ROMIPLOSTIM PLUS PREDNISO(LO)NE VS. PREDNISO(LO)NE ALONE FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY UNTREATED PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)

Registry ID

20250124

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

AMGEN CANADA INC

Last update

2026-05-26

Conditions

• THROMBOCYTOPENIA

Related clinical trials

• AN INTERVENTIONAL PHASE 2, OPEN-LABEL, ONE-ARM, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMOBOCYTOPENIA
• A RANDOMIZED CONTROLLED PHASE 3 STUDY OF ORAL PACRITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH THROMBOCYTOPENIA AND PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS.

View on source registry